# Memantine

Source: https://onco.cc/drugs/da-memantine/  
OnCo record `da-memantine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Memantine is a tablet used in moderate-to-severe dementia of the Alzheimer’s type. It is a symptom treatment, sometimes combined with a cholinesterase inhibitor.

## Summary

Kidney function and dizziness are practical issues. It is not disease-modifying and is not an antibody.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Namenda
- Modality: small molecule
- Mechanism: NMDA-receptor antagonist used for cognitive symptoms.
- Approvals: US 2003: Moderate-to-severe dementia of the Alzheimer’s type; EU 2002: Alzheimer’s dementia; UK 2002: Alzheimer’s dementia; JP 2011: Alzheimer’s dementia; CN 2006: Alzheimer’s dementia; AU 2004: Alzheimer’s dementia

## Sources

- DailyMed memantine: https://dailymed.nlm.nih.gov/dailymed/

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)

---
JSON: https://onco.cc/api/v1/entities/da-memantine.json